

GF/B45/EDP21 *Decision on the Secretariat's Recommendation on Funding from the 2020-2022 Allocation*

Approved on 19 October 2021

GF/B45/EDP21: Decision on the Secretariat's Recommendation on Funding from the 2020-2022 Allocation

The Board:

1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B45/ER19 ("Table 1");
2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

Table 1: Secretariat's Recommendation on Funding from the 2020-2022 Allocation

Please note that each country name is linked to the extranet site where supporting documents are available for review.

N	Applicant	Disease Component	Grant Name ¹	Grant End Date	Currency	Total Program Budget ²	Catalytic Funds in Grant	Domestic Commitment ³	Unfunded Quality Demand
1	Belarus	HIV/TB	BLR-C-RSPCMT	31/12/2024	US\$	21,839,591	1,000,000	HIV: 95,813,191 TB 211,434,616	9,094,881
2	Gambia	HIV/TB	GMB-C-AAITG	31/12/2023	US\$	3,064,778	-	HIV: 4,043,567 TB: 3,232,174	3,338,081
3			GMB-C-NAS	31/12/2023	US\$	15,974,728	-		
4	Indonesia	HIV	IDN-H-IAC	31/12/2023	US\$	13,602,210	2,300,000	710,712,865	28,846,955
5			IDN-H-MOH	31/12/2023	US\$	43,349,103	-		
6			IDN-H-SPIRITI	31/12/2023	US\$	30,524,768	4,000,000		
7	Kosovo	HIV/TB	QNA-C-CDF	31/12/2024	EUR	2,406,170	-	HIV: 3,452,114 TB: 3,005,180	121,326
8	Multicountry Malaria Elimination in Southern Africa E8	Malaria	QPA-M-E8S ⁴	30/09/2024	US\$	14,000,000	14,000,000	Multicountry grants exempt from co-financing requirements	3,706,803
9	South Sudan	Malaria	SSD-M-UNICEF	31/12/2023	US\$	50,339,666	-	Co-financing requirements have been waived	41,634,177
10	Sri Lanka	HIV	LKA-H-MOH	31/12/2024	US\$	6,387,963	-	20,711,964	250,300

¹ The Grant names are subject to change based on the ISO code.

² The Program budget for the Grant may be higher than the Program budget being recommended to the Board for approval where COVID-19 Response Mechanism funding has been integrated into the Grant.

³ Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies. Please note that the domestic commitments included in this report are recorded as of the date of the GAC meeting and may be updated during implementation for countries that have been granted policy flexibilities.

⁴ Please see Table 5 for details on the proposed deployment of funds for operationalizing the Multicountry Malaria Elimination in Southern Africa E8 priority area.